NCT02902874

Brief Summary

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
185

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 21, 2010

Completed
6.4 years until next milestone

First Submitted

Initial submission to the registry

September 7, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 16, 2016

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

August 17, 2026

Status Verified

August 1, 2026

Enrollment Period

10.7 years

First QC Date

September 7, 2016

Last Update Submit

August 13, 2026

Conditions

ALCL

Outcome Measures

Primary Outcomes (1)

  • Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology

    up to 78 months

Study Arms (1)

Patients treated for anaplastic large cell lymphoma ( ALCL )

EXPERIMENTAL
Other: Blood sample

Interventions

Blood sampleOTHER
Patients treated for anaplastic large cell lymphoma ( ALCL )

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies
  • Clinical data registered in SFCE database
  • Signed consent form

You may not qualify if:

  • No ALK expression on tumour
  • No consent signed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gustave Roussy

Villejuif, Val de Marne, 94805, France

Location

Related Publications (2)

  • Petrazzuolo A, Perez-Lanzon M, Martins I, Liu P, Kepp O, Minard-Colin V, Maiuri MC, Kroemer G. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death Dis. 2021 Jul 16;12(8):713. doi: 10.1038/s41419-021-03997-x.

    PMID: 34272360RESULT

  • Adriana P, Carbonnier V, De Palma FDE, Perez-Lanzon M, Verge V, Quivoron C, Lamant L, Brugieres L, Rigaud C, Ducassou S, Dourthe ME, Le Deley MC, Damm-Welk C, Woessmann W, Minard-Colin V, Maiuri MC, Kroemer G. Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study. J Transl Med. 2025 Dec 30;23(1):1434. doi: 10.1186/s12967-025-07410-5.

    PMID: 41469691DERIVED

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 7, 2016

First Posted

September 16, 2016

Study Start

April 21, 2010

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

August 17, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)